&nbsp;

Drugs Used:

lenalidomide,

dexamethasone

Quick Link(s):

Regimen Monograph

May 2022

Regimen

CAPE+BEVA

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer

Drugs Used:

capecitabine,

bevacizumab

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

CAPE+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

New Drug Funding Program

Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer

Drugs Used:

capecitabine,

trastuzumab

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

TMXF

Cancer Type:

Breast

Intent: Adjuvant

Funding:

ODB - General Benefit

tamoxifen

Drugs Used:

tamoxifen

Quick Link(s):

Regimen Monograph

Jun 2022

Regimen

FC(PO)+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

ODB - General Benefit

cyclophosphamide - oral tablets

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

Drugs Used:

riTUXimab,

fludarabine (Unfunded),

cyclophosphamide,

riTUXimab (subcut)

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

CAPECISP+ZOLB; CAPE+ZOLB(MNT)

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

zolbetuximab (Unfunded),

CISplatin,

capecitabine

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

CAPECRBP+ZOLB; CAPE+ZOLB(MNT)

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

zolbetuximab (Unfunded),

CARBOplatin,

capecitabine

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

CARFCYCLDEXA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

ODB - General Benefit

cyclophosphamide - oral tablets

Drugs Used:

carfilzomib (Unfunded),

cyclophosphamide,

dexamethasone

Quick Link(s):

Regimen Monograph

Oct 2023

Regimen

BORTDEXALENA(LD)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Without Intent for Stem Cell Transplantation

ODB Limited Use

lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to clinical criteria

ODB - General Benefit

dexamethasone

Drugs Used:

bortezomib (PDRP prior authorization),

lenalidomide,

dexamethasone